论文部分内容阅读
众所周知,心血管疾病已成为威胁人类健康的头号“杀手”,而高血压更是其中最为多见的疾病之一。据临床调查证明,全世界高血压病的患病率约为10％,欧美一些发达国家达20％。据1991年人群抽样调查,我国高血压患病率为11.88％,因此,研制开发治疗高血压病的一线药物已成为迫切需要解决的问题。 日前,在“罗氏心肾药物咨询委员会”成立大会上,罗氏公司提出了采用世界上唯一有选择性的阻断T通道钙离子的拮抗剂——博思嘉治疗高血压病的全新
It is well-known that cardiovascular disease has become the number one killer that threatens human health. Hypertension is one of the most common diseases among them. According to clinical investigations, the prevalence of hypertension in the world is about 10%, some developed countries in Europe and the United States up to 20%. According to the 1991 population sample survey, the prevalence of hypertension in China is 11.88%. Therefore, research and development of first-line drugs for the treatment of hypertension has become an urgent problem to be solved. Recently, at the inaugural meeting of “Roche Heartbeat Drug Advisory Committee”, Roche proposed to adopt the world’s only selective blocking T channel calcium antagonist - Borsgaard new treatment of hypertension